Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29554458 | 0.99 | CAPN1 (0.54) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL30647293 | 0.95 | CAPN1 (0.54) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL30712732 | 0.94 | CAPN1 (0.47) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL31750671 | 0.94 | CAPN1 (0.47) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL29691873 | 0.94 | CAPN1 (0.47) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL31259022 | 0.93 | CAPN1 (0.52) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL29554130 | 0.93 | CAPN1 (0.47) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL29760912 | 0.91 | CAPN1 (0.54) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL31751216 | 0.90 | OPRM1 (0.43) | CAPN1CTSBAPLNROPRM1OPRD1 | |
| SCHEMBL29760883 | 0.90 | CAPN1 (0.55) | CAPN1CTSBOPRM1OPRD1BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724471-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | claimed |
| WO-2025264809-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2024252366-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-12-12 | — | — | WO | claimed |
| US-11352405-B2 | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | SANOFI (FR) | 2022-06-07 | — | — | US | claimed |
| EP-4724471-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025264809-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025019280-A1 | DELIVERY SYSTEM FOR TWO OR MORE AUTOINJECTORS | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024252366-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| EP-4358996-A1 | TREATMENT OF CONGENITAL HYPERINSULINISM WITH AVEXITIDE | Eiger Biopharmaceuticals, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | SHENZHEN TURIER BIOTECH CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-3664833-B1 | GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS | SANOFI SA (FR) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022271753-A1 | TREATMENT OF CONGENITAL HYPERINSULINISM WITH AVEXITIDE | EIGER BIOPHARMACEUTICALS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | SHENZHEN TURIER BIOTECH CO., LTD. | 2022-08-23 | — | — | US | disclosed |
| US-11352405-B2 | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | SANOFI (FR) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | IAPP, PNLIP, DPP4 | CAPN1 2127/4885CTSB 110/4885APLNR 247/4885 |
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | GCGR, GLP1R, GIPR | CAPN1 2190/4885CTSB 751/4885APLNR 337/4885 |
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | GLP1R, GCGR, GIPR | CAPN1 3687/4885CTSB 372/4885APLNR 214/4885 |
| US-11352405-B2 | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | GLP1R, GCGR, GIPR | CAPN1 4524/4885CTSB 1945/4885APLNR 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.